Epix trial advances

Epix Pharmaceuticals of Lexington said today it has met its enrollment target of 330 patients for a Phase 2b trial of a drug candidate known as PRX-00023, a potential treatment for Major Depressive Disorder.

Epix said it now expects to announce the results of this trial in early 2008.

Epix also said it has completed enrollment of a Phase 2a clinical trial of PRX-03140 in Alzheimer's disease and it reaffirmed that it is on track to announce the findings of this study by the end of 2007.
(By Chris Reidy, Globe staff)